Benefits
Sleep quality and onset support
Xylaria nigripes preparations have shown benefit on sleep parameters in placebo-controlled work, supporting its traditional use for restless sleep. Zylaria® is positioned for adults seeking gentle, non-sedative botanical sleep support as part of a healthy sleep-hygiene routine.
Stress and emotional balance
Wu Ling Shen has a long history in Traditional Chinese Medicine for emotional balance and calm. Modern clinical work in adults with epilepsy showed improvement in depressive symptoms with Xylaria nigripes vs placebo, supporting its positioning as a stress and mood support botanical.
Cognitive calm without daytime sedation
Botanical sleep ingredients with GABAergic-supportive profiles aim to promote a calmer cognitive state conducive to falling and staying asleep, without the daytime grogginess sometimes associated with pharmaceutical sedative-hypnotics. Zylaria® is positioned within this category.
Adjunct to sleep-hygiene routines
Zylaria® fits within a broader sleep-support strategy that includes consistent sleep timing, light exposure management, caffeine timing, and stress regulation. It is intended as a supportive ingredient rather than a stand-alone insomnia therapeutic.
Mechanism of action
GABA precursor and GABAergic signaling support
Xylaria nigripes preparations are enriched in free amino acids including GABA itself and related precursors. Preclinical work suggests GABAergic system modulation, potentially contributing to calming and sleep-promoting effects, although direct human neuropharmacology data remains limited.
HPA-axis and stress-response modulation
Traditional and emerging mechanistic work positions Xylaria nigripes within the family of adaptogen-like botanicals that may help modulate the hypothalamic-pituitary-adrenal axis during periods of perceived stress, supporting sleep and emotional balance.
Polysaccharide and small-molecule bioactives
Xylaria nigripes contains polysaccharides and small-molecule constituents that have been characterized in natural product chemistry studies. Several have been associated with neuroprotective or anti-inflammatory activity in preclinical assays, providing additional mechanistic rationale.
Clinical trials
Multicenter, randomized, double-blind, placebo-controlled trial of Xylaria nigripes (Wu Ling capsule) vs placebo in 104 adults with epilepsy and depressive symptoms over 12 weeks. Outcomes: Hamilton Depression Rating Scale, response rates. Published in Seizure.
104 adults with epilepsy and depressive symptoms; 12-week intervention.
Xylaria nigripes treatment was associated with significantly greater improvement in depressive symptoms vs placebo (response rates 51.3% vs 35.7%). Provides controlled clinical evidence for the species' mood-supportive use, in a population with co-occurring epilepsy.
Multicenter, randomized, double-blind, placebo-controlled trial of Wuling capsule (Xylaria nigripes mycelial powder) at 3 g/day vs placebo in 186 Chinese adults with insomnia over 4 weeks, with 2-week follow-up. Outcomes: Pittsburgh Sleep Quality Index, sleep efficiency, safety. Published in Journal of Ethnopharmacology.
186 Chinese adults with insomnia; 4-week intervention plus 2-week follow-up.
Wuling capsule improved sleep quality measures vs placebo and was generally well tolerated over the trial period. Provides one of the most directly relevant placebo-controlled trials for Xylaria nigripes preparations in non-restorative sleep.